

## Appendix: Tables

1.	Sales January to September 2022 and 2021 .....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2022 and 2021 .....	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2022 vs. YTD September 2021 .....	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth .....	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States .....	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe .....	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan .....	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International .....	10

## 1. Sales January to September 2022 and 2021

CHF millions	Nine months ended 30 September		% change	
	2022	2021	At CER	In CHF
Pharmaceuticals Division	33,189	33,379	0	-1
United States	17,199	16,707	-1	3
Europe	6,100	6,610	-1	-8
Japan	3,029	3,186	7	-5
International*	6,861	6,876	0	0
Diagnostics Division	13,848	13,305	6	4
Roche Group	47,037	46,684	2	1

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Turkey, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

## 2. Quarterly sales and constant exchange rate sales growth by Division in 2022 and 2021

CHF millions	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021
Pharmaceuticals Div.	11,708	5	11,662	14	11,159	6	11,188	0	10,842	-6
United States	5,905	0	5,798	8	5,489	2	5,874	1	5,836	-6
Europe	2,125	1	2,266	19	2,072	-1	2,032	-6	1,996	4
Japan	1,378	60	1,320	46	1,337	69	865	3	827	-27
International*	2,300	2	2,278	9	2,261	0	2,417	4	2,183	-3
Diagnostics Division	4,263	18	4,455	8	5,286	24	4,662	0	3,900	-4
Roche Group	15,971	8	16,117	12	16,445	11	15,850	0	14,742	-6

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Turkey, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

### 3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2022 vs. YTD September 2021

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	4,427	17	3,283	13	808	25	-	-	336	37
Perjeta	3,090	5	1,135	1	661	-16	175	-1	1,119	33
Hemlibra	2,778	28	1,684	22	542	32	277	20	275	76
Tecentriq	2,692	10	1,451	9	573	19	326	-5	342	16
Actemra/RoActemra	2,039	-23	914	-33	602	-3	256	1	267	-39
Herceptin	1,672	-18	376	-28	329	-13	40	-28	927	-15
Avastin	1,652	-29	497	-36	158	-51	378	-15	619	-21
Xolair	1,625	10	1,625	10	-	-	-	-	-	-
MabThera/Rituxan	1,596	-20	1,002	-20	156	-18	24	-10	414	-23
Kadcyla	1,590	11	619	-3	508	8	101	21	362	50
Alecensa	1,127	16	331	20	218	6	169	5	409	26
Activase/TNKase	881	-8	836	-9	-	-	-	-	45	5
Lucentis	800	-25	800	-25	-	-	-	-	-	-
Evrysdi	793	101	348	24	253	335	60	**	132	100
Ronapreve	631	-36	-	-	102	-81	452	42	77	-49
Esbriet	590	-25	381	-34	186	-1	-	-	23	-22
Gazyva	539	8	251	3	144	-7	39	-7	105	89
Phesgo	526	150	217	112	263	204	-	-	46	99
Pulmozyme	414	-1	280	2	73	-12	-	-	61	-2
CellCept	386	-12	30	-19	101	-6	43	-6	212	-14
Polivy	290	79	121	74	84	41	68	161	17	111
Vabysmo	282	-	253	-	4	-	24	-	1	-

Erivedge	200	2	126	-6	44	7	-	-	30	35
Enspryng	133	108	37	135	6	**	86	87	4	456
Rozlytrek	53	50	34	40	9	83	5	22	5	174
Cotellic	35	1	10	0	11	-9	-	-	14	13
Gavreto	20	299	15	200	5	**	-	-	-	-
Xofluza	6	-	2	-	-	-	-	-	4	34
Susvimo	3	-	3	-	-	-	-	-	-	-
Lunsumio	1	-	-	-	1	-	-	-	-	-
Pharma other	2,318	-15	538	-20	259	-20	506	-10	1,015	-13
Pharma total sales	33,189	0	17,199	-1	6,100	-1	3,029	7	6,861	0

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Turkey, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

\*\* Over 500%

#### 4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021
Ocrevus	1,283	7	1,334	25	1,449	18	1,461	17	1,517	16
Perjeta	1,006	2	981	3	993	1	1,068	9	1,029	5
Hemlibra	779	37	850	38	853	30	973	31	952	23
Tecentriq	878	23	838	17	825	8	933	13	934	9
Actemra/RoActemra	1,048	57	872	21	792	3	663	-23	584	-42
Herceptin	665	-26	633	-6	607	-19	572	-11	493	-23
Avastin	745	-37	666	-30	581	-32	561	-27	510	-28
Xolair	529	8	526	14	456	9	569	13	600	8
MabThera/Rituxan	589	-42	597	-26	564	-21	553	-20	479	-19
Kadcyla	501	11	522	16	511	9	563	18	516	6
Alecensa	357	18	368	15	361	23	384	16	382	11
Activase/TNKase	323	3	391	22	247	-20	312	1	322	-5
Lucentis	352	-10	336	2	256	-26	316	-9	228	-39
Evrysdi	153	*	206	347	226	189	274	65	293	93
Ronapreve	489	-	546	-	587	272	22	-91	22	-92
Esbriet	263	-5	250	-7	241	-6	216	-21	133	-48
Gazyva	177	10	177	10	165	7	184	9	190	9
Phesgo	117	*	127	*	146	410	179	168	201	76
Pulmozyme	138	-7	152	5	136	-3	143	2	135	-3
CellCept	155	3	139	-2	134	-12	136	-3	116	-20

\* Over 500%

**5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States**

CHF millions	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021
Ocrevus	930	0	998	23	1,050	12	1,090	10	1,143	17
Perjeta	376	2	337	-2	362	-1	378	4	395	0
Hemlibra	480	36	498	33	520	28	578	24	586	16
Tecentriq	461	10	416	2	446	10	505	15	500	3
Actemra/RoActemra	611	143	461	67	380	22	284	-31	250	-61
Herceptin	153	-52	135	-34	144	-26	119	-29	113	-29
Avastin	215	-50	177	-45	178	-39	164	-36	155	-31
Xolair	529	8	526	14	456	9	569	13	600	8
MabThera/Rituxan	342	-49	355	-32	347	-20	344	-24	311	-14
Kadcyla	212	0	200	3	204	0	211	-1	204	-8
Alecensa	96	9	103	18	99	25	108	14	124	22
Activase/TNKase	309	2	376	22	234	-21	297	1	305	-6
Lucentis	352	-10	336	2	256	-26	316	-9	228	-39
Evrysdi	102	*	97	112	109	36	118	28	121	13
Ronapreve	-	-	-	-	-	-	-	-	-	-
Esbriet	195	-2	176	-7	170	-4	143	-28	68	-67
Gazyva	79	3	81	11	75	0	86	3	90	7
Phesgo	46	*	53	236	60	187	78	134	79	62
Pulmozyme	89	-10	101	6	87	0	97	5	96	2
CellCept	12	-18	10	-31	10	-15	10	-17	10	-25

\* Over 500%

**6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe**

CHF millions	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021
Ocrevus	267	36	227	26	280	34	259	34	269	11
Perjeta	269	-8	265	-8	228	-21	229	-12	204	-15
Hemlibra	148	26	169	53	170	31	190	29	182	36
Tecentriq	181	16	193	41	183	14	200	24	190	17
Actemra/RoActemra	207	10	252	18	220	-4	200	-2	182	-3
Herceptin	130	-20	137	-3	122	-13	111	-9	96	-18
Avastin	89	-69	84	-49	58	-56	58	-49	42	-47
Xolair	-	-	-	-	-	-	-	-	-	-
MabThera/Rituxan	69	-33	65	-13	54	-19	51	-16	51	-18
Kadcyla	172	16	179	16	172	8	178	12	158	3
Alecensa	73	7	76	9	75	5	74	8	69	5
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Evrysdi	35	-	51	*	68	*	84	227	101	216
Ronapreve	85	-	159	-	62	-61	3	-99	37	-54
Esbriet	65	0	67	0	62	-5	65	1	59	1
Gazyva	61	10	56	2	46	-5	49	-8	49	-9
Phesgo	53	-	71	-	76	*	87	188	100	107
Pulmozyme	29	-10	28	-15	26	-11	25	-12	22	-12
CellCept	38	-2	39	3	34	-7	34	-7	33	-5

\* Over 500%



## 7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021
Ocrevus	-	-	-	-	-	-	-	-	-	-
Perjeta	68	0	68	-3	59	-1	61	-1	55	-1
Hemlibra	94	29	105	30	84	15	96	24	97	22
Tecentriq	130	75	131	34	107	-5	111	-9	108	0
Actemra/RoActemra	103	25	97	5	87	12	87	-2	82	-4
Herceptin	20	-37	19	-36	15	-30	13	-27	12	-28
Avastin	172	5	172	0	131	-12	132	-13	115	-19
Xolair	-	-	-	-	-	-	-	-	-	-
MabThera/Rituxan	11	-30	11	-17	8	-15	9	-2	7	-13
Kadcyla	34	59	36	42	32	28	36	20	33	16
Alecensa	63	11	66	5	54	7	60	5	55	4
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Evrysdi	3	-	16	-	17	-	21	-	22	*
Ronapreve	360	-	285	-	483	-	-16**	-	-15**	-100
Esbriet	-	-	-	-	-	-	-	-	-	-
Gazyva	16	10	15	-7	15	8	13	-10	11	-17
Phesgo	-	-	-	-	-	-	-	-	-	-
Pulmozyme	-	-	1	22	-	-	-	-	-	-
CellCept	17	-7	18	-9	14	-8	15	-9	14	-1

\* Over 500%

\*\*Effect of currency revaluation (CHF/JPY) on CHF483mn Q1 2022 Ronapreve sales

**8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International\***

CHF millions	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021
Ocrevus	86	35	109	51	119	29	112	62	105	26
Perjeta	293	16	311	24	344	32	400	37	375	30
Hemlibra	57	138	78	55	79	63	109	115	87	53
Tecentriq	106	62	98	24	89	0	117	17	136	30
Actemra/RoActemra	127	-14	62	-55	105	-30	92	-44	70	-44
Herceptin	362	-7	342	17	326	-18	329	-3	272	-22
Avastin	269	-11	233	-24	214	-23	207	-17	198	-23
Xolair	-	-	-	-	-	-	-	-	-	-
MabThera/Rituxan	167	-25	166	-15	155	-23	149	-13	110	-32
Kadcyla	83	16	107	38	103	26	138	81	121	46
Alecensa	125	40	123	25	133	45	142	29	134	9
Activase/TNKase	14	17	15	7	13	-3	15	4	17	12
Lucentis	-	-	-	-	-	-	-	-	-	-
Evrysdi	13	-	42	**	32	**	51	-5	49	231
Ronapreve	44	-	102	-	42	-	35	-68	-	-
Esbriet	3	-73	7	-36	9	-36	8	-36	6	109
Gazyva	21	43	25	56	29	75	36	101	40	91
Phesgo	18	-	3	**	10	**	14	278	22	20
Pulmozyme	20	12	22	45	23	-4	21	14	17	-16
CellCept	88	13	72	3	76	-14	77	3	59	-29

\* Asia-Pacific, CEETRIS (Central Eastern Europe, Turkey, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

\*\* Over 500%